An Integrative Multimodal Model for Early Diagnosis of Dementia and Differential Diagnosis of Alzheimer's Disease Using Neuroimaging, Polygenic Risk, and Cognitive Assessments
Multimodal integration of cognitive, neuroimaging, and polygenic data in the MHS-RWD tool yields strong discrimination for both early diagnosis of dementia and AD differential diagnosis, which could support etiologically informed dementia decisions in real-world settings, with potential utility in primary care.
Abstract
Background: Early diagnosis and etiological classification of dementia remain challenging, as clinicians typically lack tools to integrate cognitive, neuroimaging, and genetic data quantitatively. We developed and validated multimodal risk models to support early diagnosis of dementia and differential diagnosis of Alzheimer's disease (AD) versus non-AD dementias in real-world clinical settings and translated model outputs into individualized risk reports. Methods: Utilizing real-world clinical cohorts (n = 1,100 for early diagnosis of dementia, using clinical diagnoses up to three years after clinical assessment; n = 788 for AD differential diagnosis) from Norwegian Memory Clinics, we trained and validated the Multimodal Hazard Score for Real-World Data (MHS-RWD) model integrating demographics (age, sex), cognitive assessments (MMSE-NR3 or CERAD 10-word delayed recall), the MRI-derived Imaging Hazard Score, and the Polygenic Hazard Score. Discrimination performance was examined using the area under the receiver operating characteristic curve (AUC). Results: In real-world clinical data, the MHS-RWD consistently outperformed any single predictor used alone. For early diagnosis of dementia, the full model achieved an AUC of 0.89 in females and 0.84 in males. For the differential diagnosis of AD from other dementias, the multimodal model yielded an AUC of 0.91 in females and 0.83 in males. A patient-level risk report was designed to present individualized risk estimates. Conclusions: Multimodal integration of cognitive, neuroimaging, and polygenic data in the MHS-RWD tool yields strong discrimination for both early diagnosis of dementia and AD differential diagnosis. The tool relies on data obtainable in clinical care, and genetic information that is becoming increasingly available in routine practice. Delivered through intuitive patient-level risk reports, it could support etiologically informed dementia decisions in real-world settings, with potential utility in primary care.
BackgroundThe identification and early diagnosis of mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) dementia are critical for timely intervention, yet implementation of biomarker-based diagnostics in the Italian healthcare system remains limited.ObjectiveTo characterize the real-world diagnostic journ...
S. Ippati, Federico Torelli, Giovanna Zamboni et al.· Journal of Alzheimer's Disea...· 0 citations
MRI-derived brain-PAD predicts progression to dementia in memory clinic patients with SCD or MCI and provided additional predictive value to visual rating scales in patients with SCD and mild cognitive impairment.
S. de Vries, K. Farkas, Hanneke F. M. Rhodius-Meester et al.· Neurology· 0 citations
Identifying individuals with mild cognitive impairment (MCI) likely to progress to Alzheimer's disease (AD) is important for patient management and clinical trial enrollment. Although cognitive assessments, genetics, neuroimaging, and fluid biomarkers are each associated with disease progression, their predictive value...
Accurate prediction of progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is important for prognosis, patient management, and clinical trial enrollment. Cognitive and functional assessments are routinely used in memory clinics, but their relative predictive value remains unclear. We sought to...
Timely detection of cognitive impairment due to Alzheimer’s disease (AD) is increasingly important as disease modifying therapies become available. Current diagnostic pathways in primary health care (PHC) rely mainly on clinical assessment and brief cognitive screening tools, which lack sensitivity for early impairment...
Sandar Aye, Signe Åhrberg, Axel C. Carlsson et al.· Alzheimer's Research & Thera...· 0 citations
INTRODUCTION
Young-onset Alzheimer's disease (YOAD), defined by symptom onset before 65 years, represents a distinct subtype of Alzheimer's disease with important diagnostic and therapeutic implications. Compared with late-onset Alzheimer's disease (LOAD), YOAD shows greater phenotypic heterogeneity, more frequent atyp...
A. Schild, C. Bartels, R. Dodel· Expert Review of Neurotherap...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.